Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

October 31, 2012

Conditions
Ovarian Cancer
Interventions
DRUG

Gleevec/Paclitaxel

"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."

Trial Locations (1)

10016

NYU cancer center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

NYU Langone Health

OTHER